Compass Pathways Rises After 1-Year Psilocybin Data in Treatment-Resistant Depression
Open-label Part C data showed extra MADRS improvement and ~30% remission after another 25 mg dose. Safety was unchanged. Launch targeted for H1 2027.
/ 10 items
#CMPS↓
Compass Pathways Shares Jump on Strong COMP360 Phase 3 Data and Clear Path to 2027 Launch
Compass Pathways reports strong Q2: Phase 3 wins for COMP360 in TRD, $433M cash, rolling NDA, and commercial launch planned for first half 2027.
Wells Fargo Sees Psychedelics Market Hitting $11 Billion by 2035
Wells Fargo sees a booming psychedelic depression market, with new treatments challenging Spravato and creating big opportunities for biotech firms.
Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Wall Street Boosts Compass Pathways as COMP360 Durability Data Strengthens Path to 2027 Approval
Positive six-month COMP360 results trigger analyst upgrades and higher price targets for Compass Pathways. Strong durability data clears path to potential 2027 FDA approval in treatment-resistant depression.
Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.